Brought to you by 
Gilead gets global rights to Tibotec's TMC278
30 Nov 2015
Executive Summary
Gilead Sciences has received exclusive worldwide rights (excluding Japan) to Tibotec Pharmaceuticals' (a Johnson & Johnson division that works on infectious disease therapeutics) TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor. Gilead will combine TMC278 with its Truvada (emtricitabine/tenofovir disoproxil) to create a once-daily fixed-dose antiretroviral therapy for HIV-1 infected adults.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gilead gets global rights to Tibotec's TMC278
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice